JPWO2022248885A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022248885A5
JPWO2022248885A5 JP2023573109A JP2023573109A JPWO2022248885A5 JP WO2022248885 A5 JPWO2022248885 A5 JP WO2022248885A5 JP 2023573109 A JP2023573109 A JP 2023573109A JP 2023573109 A JP2023573109 A JP 2023573109A JP WO2022248885 A5 JPWO2022248885 A5 JP WO2022248885A5
Authority
JP
Japan
Prior art keywords
alkyl
independently selected
groups
optionally substituted
membered heterocycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519170A (ja
JP2024519170A5 (https=
Publication date
Priority claimed from GBGB2107637.7A external-priority patent/GB202107637D0/en
Application filed filed Critical
Priority claimed from PCT/GB2022/051367 external-priority patent/WO2022248885A2/en
Publication of JP2024519170A publication Critical patent/JP2024519170A/ja
Publication of JPWO2022248885A5 publication Critical patent/JPWO2022248885A5/ja
Publication of JP2024519170A5 publication Critical patent/JP2024519170A5/ja
Pending legal-status Critical Current

Links

JP2023573109A 2021-05-28 2022-05-27 化合物 Pending JP2024519170A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2107637.7 2021-05-28
GBGB2107637.7A GB202107637D0 (en) 2021-05-28 2021-05-28 Compounds
GB2118635.8 2021-12-21
GB202118635 2021-12-21
PCT/GB2022/051367 WO2022248885A2 (en) 2021-05-28 2022-05-27 Compounds

Publications (3)

Publication Number Publication Date
JP2024519170A JP2024519170A (ja) 2024-05-08
JPWO2022248885A5 true JPWO2022248885A5 (https=) 2025-06-04
JP2024519170A5 JP2024519170A5 (https=) 2025-06-04

Family

ID=82019773

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573109A Pending JP2024519170A (ja) 2021-05-28 2022-05-27 化合物

Country Status (10)

Country Link
US (1) US20240279241A1 (https=)
EP (1) EP4347589A2 (https=)
JP (1) JP2024519170A (https=)
KR (1) KR20240013776A (https=)
AU (1) AU2022279653A1 (https=)
BR (1) BR112023024906A2 (https=)
CA (1) CA3216294A1 (https=)
IL (1) IL308438A (https=)
MX (1) MX2023014138A (https=)
WO (1) WO2022248885A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12479834B2 (en) 2019-11-29 2025-11-25 Taiho Pharmaceutical Co., Ltd. Phenol compound or salt thereof
EP4161926A4 (en) * 2020-06-03 2024-06-19 Yumanity Therapeutics, Inc. PYRIDOPYRIMIDINES AND THEIR METHODS OF USE
WO2023018812A1 (en) * 2021-08-10 2023-02-16 Amgen Inc. Heterocyclic compounds and methods of use
TW202328124A (zh) * 2021-08-18 2023-07-16 大陸商北京加科思新藥研發有限公司 1,4-氧雜氮雜環庚烷衍生物及其用途
WO2023061294A1 (zh) * 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
TW202334138A (zh) 2021-11-05 2023-09-01 美商新領域醫藥公司 癌症治療方法
JP2024543879A (ja) * 2021-11-24 2024-11-26 メルク・シャープ・アンド・ドーム・エルエルシー Kras変異型タンパク質の小分子阻害剤
EP4444289A4 (en) * 2021-12-08 2025-12-17 Kineta Inc PYRIDOPYRIMIDINS AND METHODS FOR THEIR USE
CN118556063A (zh) * 2022-01-21 2024-08-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
CN118900838A (zh) * 2022-03-24 2024-11-05 百济神州有限公司 杂环化合物、其组合物及其治疗方法
WO2023213269A1 (en) * 2022-05-06 2023-11-09 Zai Lab (Shanghai) Co., Ltd. Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof
WO2023246777A1 (en) * 2022-06-20 2023-12-28 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024008068A1 (en) * 2022-07-04 2024-01-11 Jacobio Pharmaceuticals Co., Ltd. K-ras mutant protein inhibitors
WO2024012519A1 (zh) * 2022-07-13 2024-01-18 北京华森英诺生物科技有限公司 Pan-kras抑制剂
CN117624170A (zh) * 2022-08-24 2024-03-01 泰励生物科技(上海)有限公司 具有抗kras突变肿瘤活性的化合物
CN120077051A (zh) * 2022-10-21 2025-05-30 苏州亚盛药业有限公司 Kras抑制剂
WO2024112654A1 (en) 2022-11-21 2024-05-30 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
CN118165011A (zh) * 2022-12-08 2024-06-11 润佳(上海)医药工程有限公司 Kras抑制剂及其用途
WO2024125600A1 (zh) * 2022-12-14 2024-06-20 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物,及其制备和治疗用途
WO2024138206A1 (en) * 2022-12-23 2024-06-27 Frontier Medicines Corporation Fluoropyridopyrimidine and fluoroquinazoline derivaties and methods of use thereof
WO2024209339A1 (en) * 2023-04-05 2024-10-10 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
KR20260015208A (ko) 2023-05-12 2026-02-02 재즈 파마슈티칼즈 아일랜드 리미티드 암 치료에 유용한 g12d 돌연변이체 kras의 조절제로서 피라졸로[4,3-f]퀴나졸린 유도체
CN119101070A (zh) * 2023-06-07 2024-12-10 上海璎黎药业有限公司 一种含氮杂环化合物、其药物组合物及应用
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
AU2024323424A1 (en) 2023-08-17 2026-03-05 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
TW202528315A (zh) 2023-09-21 2025-07-16 美商樹線生物科學公司 螺環二氫哌喃并吡啶KRas抑制劑
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025085748A1 (en) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025163494A1 (en) 2024-01-29 2025-08-07 Jazz Pharmaceuticals Ireland Ltd. Condensed azines for the treatment of cancer
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025235740A1 (en) * 2024-05-08 2025-11-13 Merck Sharp & Dohme Llc Small molecule inhibitors of kras proteins
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201942115A (zh) * 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
WO2020146613A1 (en) * 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2021041671A1 (en) 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4192585A4 (en) * 2020-08-04 2024-08-21 Mirati Therapeutics, Inc. Kras g12d inhibitors
CN115968286A (zh) * 2020-08-26 2023-04-14 益方生物科技(上海)股份有限公司 杂芳基化合物,其制备方法和用途
US20230081426A1 (en) * 2020-09-18 2023-03-16 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
US20230365563A1 (en) * 2020-09-30 2023-11-16 Shanghai Pharmaceuticals Holding Co., Ltd. Quinazoline compound and application thereof
WO2022098625A1 (en) * 2020-11-03 2022-05-12 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022132200A1 (en) * 2020-12-15 2022-06-23 Mirati Therapeutics, Inc. Azaquinazoline pan-kras inhibitors
CN113999226B (zh) * 2020-12-22 2023-01-06 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物的制备及其应用方法
WO2022256459A1 (en) * 2021-06-01 2022-12-08 Quanta Therapeutics, Inc. Kras modulators and uses thereof

Similar Documents

Publication Publication Date Title
JPWO2022248885A5 (https=)
JPWO2022258974A5 (https=)
RU2219180C2 (ru) Производные 1,5-дигидропиразоло[3,4-d]-пиримидинона
ES3009132T3 (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1h)-one derivatives, salts thereof and their use in therapy
RU2309951C2 (ru) Производные никотинамида, способы их получения, фармацевтическая композиция на их основе и применение
JP2018511631A5 (https=)
JP2015533177A5 (https=)
RU2010131833A (ru) Способы получения производных хиназолинона
BG104960A (en) Bicyclic pirimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
JP2009515992A5 (https=)
CY1108254T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
RU2019132666A (ru) Макроциклические соединения в качестве ингибиторов киназы ros1
RU2009146832A (ru) Производные хиназолиноксима в качестве ингибиторов hsp90
JP2008538750A5 (https=)
CA2434834A1 (en) 6-substituted pyrido-pyrimidines
RU2014151009A (ru) Пиразолопиримидоновые и пиразолопиридоновые ингибиторы танкиразы
JP2006524225A5 (https=)
RU2003107683A (ru) Производные хиназолина
JPWO2023018809A5 (https=)
ME01541B (me) DERIVATI HIDROKSIBENZAMIDA l NJIHOVA PRIMJENA KAO INHIBITORA HSP90
HUP9802534A2 (hu) Neurotranszmitter újrafelvételt gátló kondenzált tropánszármazékok és előállításuk, e vegyületeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
BR112016011072B1 (pt) Composto 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9- hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h) -ona e composição farmacêutica contendo o referido composto
ES2937810T3 (es) Derivado de sulfonamida con esqueleto de cumarina
RU2013150102A (ru) Ингибиторы parp для лечения cipn
CA2439787A1 (en) Nitrogen-based camptothecin derivatives